Financial Data and Key Metrics Changes - Revenue for the year was $75 million, a significant increase from approximately $29 million in 2024, with $36 million stemming from settling patent infringement claims against Bruker [13][14] - The net loss for the year was roughly $146 million, an improvement compared to a loss of about $163 million in the previous year, resulting in a loss of $0.49 per share [14] - Operating activities used approximately $130 million in cash and equivalents for the year [14][16] Business Line Data and Key Metrics Changes - The company initiated work on one additional partner-initiated program, bringing the cumulative total to 104 programs with downstream participation [10] - The focus on proprietary pipeline advancement led to a decision to stop reporting on partner-initiated program starts on a quarterly basis starting in 2026 [10] Market Data and Key Metrics Changes - The company has approximately $700 million in available liquidity, including $560 million in cash and equivalents and $140 million in committed government funding [10][16] - The clinical pipeline includes 19 molecules that have reached the clinic, with ABCL635 advancing into a Phase 2 study [11][12] Company Strategy and Development Direction - The company aims to become a vertically integrated clinical-stage biotech, having successfully transitioned from building its platform to focusing on pipeline development [4][5] - Key priorities for 2026 include delivering top-line readouts for ABCL635 Phase 2 and ABCL575 Phase 1 studies, advancing ABCL688 and ABCL386 through IND-enabling activities, and adding one new development candidate [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ABCL635, with a positive Phase 2 readout expected to lead to late-stage development [8][9] - The company acknowledges the uncertainties in drug development but remains committed to advancing its pipeline and believes it has sufficient liquidity to fund operations beyond the next three years [17] Other Important Information - The company has made significant investments in property, plant, and equipment to establish clinical manufacturing capabilities, which are now substantially complete [15] - The clinical manufacturing facility allows for better control of the supply chain and improved flexibility [15] Q&A Session Summary Question: Potential for ABCL575 as a combination regimen - Management believes in the potential of OX40 ligand as a class and is exploring combination opportunities internally and with external parties [21][22] Question: Oncology-based BMS studies - Management sees opportunities in breast and prostate cancer, particularly for patients experiencing severe hot flashes [26] - Differentiation in safety and convenience is viewed as a major factor in the product profile [27] Question: Update on ABCL635 target engagement data - The Phase I portion of the study will be released alongside the Phase II data in Q3, with no announcements expected before then [32] Question: Clinical trial infrastructure capacity - The company has reshaped its internal resources to support multiple programs in clinical development and is committed to building operational capacity [43][44] Question: Decision factors for ABCL575 development - The decision will largely depend on external factors, including partnership opportunities and the competitive landscape [45]

Financial Data and Key Metrics Changes - The company reported revenue of $9 million for the quarter, an increase from approximately $7 million in the same quarter of the previous year, reflecting a growth of about 29% [8] - Research and development expenses for the quarter were $55 million, which is approximately $14 million more than last year, indicating a significant investment in internal and co-development programs [9] - The net loss for the quarter was roughly $57 million, compared to a loss of about $51 million in the same quarter of the previous year, resulting in a loss of $0.19 per share [9][10] - The company ended the quarter with approximately $680 million in available liquidity, including $520 million in cash and cash equivalents and $160 million in committed government funding [4][11] Business Line Data and Key Metrics Changes - The company initiated one additional partner-initiated program in the third quarter, bringing the cumulative total to 103 programs with downstream participation [7] - The cumulative total of molecules that have reached the clinic remains at 18, including both the company's own pipeline and those led by partners [7] Market Data and Key Metrics Changes - The company is transitioning from a partnership model to focusing on internal drug development, with the first two programs now in clinical development [4][16] - The company aims to advance at least one more development candidate into IND enabling studies by the end of the year [4][26] Company Strategy and Development Direction - The company has completed its transition to a clinical-stage biotech and is focusing on advancing its internal pipeline while leveraging its clinical manufacturing capabilities [4][11] - The appointment of Dr. Sarah Nunberg as Chief Medical Officer is seen as a strategic move to enhance clinical development expertise within the company [5][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving corporate priorities and advancing development candidates, with a focus on building a strong pre-clinical pipeline [11] - The company is encouraged by the progress of its clinical trials and expects to provide updates on its pipeline in the coming year [21][41] Other Important Information - The company has received commitments for funding from the Government of Canada's Strategic Innovation Fund and the Government of British Columbia, which will support its internal pipeline advancements [10][11] - The company is managing its capital needs effectively and believes it has sufficient liquidity to fund operations well beyond the next three years [11] Q&A Session Summary Question: How to think about partner-initiated programs in the clinic? - Management acknowledged that partner-initiated programs have been slower to progress than anticipated, with some taking as long as six years to move into clinical development [15] Question: Why was now the appropriate time to bring Dr. Nunberg in as CMO? - Management indicated that the transition to drug development on their own behalf necessitated the need for a senior executive with clinical development experience [16] Question: Can you provide insights on the data disclosure strategy for the phase I 635 study? - Management plans to make a single disclosure after completing the proof of concept part of the study, expected around mid-next year [21] Question: What are the expected benefits of 635 versus existing hormonal treatments? - Management clarified that 635 is being developed as an alternative to menopausal hormone therapy, targeting women who cannot use traditional treatments [35] Question: What differentiates 575 from existing competitors? - Management highlighted that 575 aims for less frequent dosing compared to competitors, which could be a significant advantage in the clinical setting [39]

Financial Data and Key Metrics Changes - The company reported revenue of $9 million for Q3 2025, an increase from approximately $7 million in the same quarter of the previous year, primarily from research fees related to partnered programs [9] - Research and development expenses for the quarter were $55 million, an increase of about $14 million compared to the same quarter last year, driven by specific investments of $15 million in two internal programs [10] - The net loss for the quarter was approximately $57 million, compared to a loss of about $51 million in the same quarter of the previous year, resulting in a loss of $0.19 per share [10][11] - The company ended the quarter with approximately $680 million in available liquidity, including $520 million in cash and cash equivalents and $160 million in committed government funding [4][12] Business Line Data and Key Metrics Changes - The company initiated one additional partner-initiated program in Q3 2025, bringing the cumulative total to 103 programs with downstream participation [7] - The cumulative total of molecules that have reached the clinic remained at 18, including both the company's own pipeline and those led by partners [7][8] Market Data and Key Metrics Changes - The company is transitioning from a partnership model to focusing on internal drug development, with the first two programs now in clinical development [16] - The company aims to advance at least one more development candidate into IND enabling studies by the end of the year [4][25] Company Strategy and Development Direction - The company has completed its transition from a platform company to a clinical-stage biotech, with a focus on advancing its internal pipeline [4] - The appointment of Dr. Sarah Nunberg as Chief Medical Officer is seen as a strategic move to enhance clinical development capabilities [5][17] - The company is confident in its ability to fund pipeline investments well beyond the next three years [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the progress of partner-initiated programs has been slower than anticipated, with some programs taking up to six years to move into clinical development [16] - The company is encouraged by the progress of its clinical trials and expects to provide updates on its pipeline in the coming year [21][36] Other Important Information - The company has received commitments for funding from the Government of Canada's Strategic Innovation Fund and the Government of British Columbia, which are not reflected on the balance sheet [11][12] - The company is focused on advancing its two lead programs through their phase I clinical studies while building a strong pre-clinical pipeline [12] Q&A Session Summary Question: How to think about partner-initiated programs in the clinic? - Management noted that the partner-initiated programs have been stagnant since 2024, but they expect some to move forward into clinical development, albeit at a slower pace than initially anticipated [16] Question: Why was now the appropriate time to bring Dr. Nunberg in as CMO? - Management indicated that the transition to drug development on their own behalf necessitated the need for a senior executive with clinical development experience [17] Question: What is the data disclosure strategy for the phase I 635 study? - Management expects to make a single disclosure after completing the proof of concept part, likely around mid-next year, focusing on safety and efficacy [21] Question: How is enrollment going in the phase I trial for 575? - Management confirmed that enrollment is proceeding as expected and is on track [24] Question: What are the benefits of 635 versus existing hormonal treatments for hot flashes? - Management clarified that 635 is being developed as an alternative to menopausal hormone therapy, targeting women who cannot use MHT due to contraindications or adverse events [31]